Xilio Therapeutics, Inc. Research and Development Expense
Xilio Therapeutics, Inc. (XLO) reported Research and Development Expense of $14.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Xilio Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $14.56M, a 5.03% decline year-over-year.
- Xilio Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $19.83M, a 139.92% increase year-over-year.
- Xilio Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $18.12M, a 105.09% increase year-over-year.
- Xilio Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $14.32M, a 33.11% increase year-over-year.
- Xilio Therapeutics, Inc. research and development expense for fiscal 2025 was $56.04M, a 35.98% increase from fiscal 2024.
- Xilio Therapeutics, Inc. research and development expense for fiscal 2024 was $41.21M, a 20.95% decline from fiscal 2023.
- Xilio Therapeutics, Inc. research and development expense for fiscal 2023 was $52.14M, a 11.93% decline from fiscal 2022.
- Xilio Therapeutics, Inc. research and development expense for fiscal 2022 was $59.20M, a 15.65% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.56M 10-Q · filed 2026-08-12 | $34.39M 10-Q · filed 2026-08-12 | $52.51M derived: sum of 3 quarters · filed 2026-08-12 | $66.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $19.83M 10-Q · filed 2026-05-12 | $37.95M derived: sum of 2 quarters · filed 2026-05-12 | $52.27M derived: sum of 3 quarters · filed 2026-05-12 | $67.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $18.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $32.44M derived: sum of 2 quarters · filed 2026-03-23 | $47.77M derived: sum of 3 quarters · filed 2026-08-12 | $56.04M 10-K · filed 2026-03-23 |
| 2025-09-30 | $14.32M 10-Q · filed 2025-11-13 | $29.65M derived: sum of 2 quarters · filed 2026-08-12 | $37.92M 10-Q · filed 2025-11-13 | $46.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $15.33M 10-Q · filed 2026-08-12 | $23.60M 10-Q · filed 2026-08-12 | $32.43M derived: sum of 3 quarters · filed 2026-08-12 | $43.19M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $8.27M 10-Q · filed 2026-05-12 | $17.10M derived: sum of 2 quarters · filed 2026-05-12 | $27.86M derived: sum of 3 quarters · filed 2026-05-12 | $39.08M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $8.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $19.59M derived: sum of 2 quarters · filed 2026-03-23 | $30.81M derived: sum of 3 quarters · filed 2026-03-23 | $41.21M 10-K · filed 2026-03-23 |
| 2024-09-30 | $10.76M 10-Q · filed 2025-11-13 | $21.98M derived: sum of 2 quarters · filed 2025-11-13 | $32.38M 10-Q · filed 2025-11-13 | $44.11M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $11.22M 10-Q · filed 2025-08-14 | $21.62M 10-Q · filed 2025-08-14 | $33.35M derived: sum of 3 quarters · filed 2025-08-14 | $44.40M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $10.40M 10-Q · filed 2025-05-08 | $22.14M derived: sum of 2 quarters · filed 2025-05-08 | $33.19M derived: sum of 3 quarters · filed 2025-05-08 | $46.41M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $11.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $22.79M derived: sum of 2 quarters · filed 2025-03-11 | $36.01M derived: sum of 3 quarters · filed 2025-03-11 | $52.14M 10-K · filed 2025-03-11 |
| 2023-09-30 | $11.05M 10-Q · filed 2024-11-07 | $24.27M derived: sum of 2 quarters · filed 2024-11-07 | $40.40M 10-Q · filed 2024-11-07 | $55.40M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $13.22M 10-Q · filed 2024-08-08 | $29.35M 10-Q · filed 2024-08-08 | $44.35M derived: sum of 3 quarters · filed 2024-08-08 | $57.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $16.13M 10-Q · filed 2024-05-14 | $31.13M derived: sum of 2 quarters · filed 2024-05-14 | $44.17M derived: sum of 3 quarters · filed 2024-05-14 | $60.41M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $28.04M derived: sum of 2 quarters · filed 2024-04-01 | $44.28M derived: sum of 3 quarters · filed 2024-04-01 | $59.20M 10-K · filed 2024-04-01 |
| 2022-09-30 | $13.04M 10-Q · filed 2023-11-09 | $29.28M derived: sum of 2 quarters · filed 2023-11-09 | $44.20M 10-Q · filed 2023-11-09 | $55.56M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $16.25M 10-Q · filed 2023-08-14 | $31.17M 10-Q · filed 2023-08-14 | $42.52M derived: sum of 3 quarters · filed 2023-08-14 | $52.99M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $14.92M 10-Q · filed 2023-05-09 | $26.27M derived: sum of 2 quarters · filed 2023-05-09 | $36.74M derived: sum of 3 quarters · filed 2023-05-09 | $54.49M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $11.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $21.82M derived: sum of 2 quarters · filed 2023-03-02 | $39.57M derived: sum of 3 quarters · filed 2023-03-02 | $51.19M 10-K · filed 2023-03-02 |
| 2021-09-30 | $10.47M 10-Q · filed 2022-11-09 | $28.21M derived: sum of 2 quarters · filed 2022-11-09 | $39.84M 10-Q · filed 2022-11-09 | $57.50M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $17.75M 10-Q · filed 2022-08-09 | $29.37M 10-Q · filed 2022-08-09 | $47.03M derived: sum of 3 quarters · filed 2022-08-09 | $58.49M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $11.62M 10-Q · filed 2022-05-12 | $29.29M derived: sum of 2 quarters · filed 2022-05-12 | $40.75M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $17.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $29.13M derived: sum of 2 quarters · filed 2022-03-01 | $43.91M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $11.46M 10-Q · filed 2021-12-02 | $26.24M 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |